State-of-the-art antibody technology andrecent discoveries in neuroimmunolgy.

Braincure Biotech is dedicated to pursuing the development and commercialization of novel treatment approaches in the fight against dementias, with a particular focus on Alzheimer’s Disease.

Science that changes life.

Patent-pending technology has allowed for the development of a medical device that can be implanted using a minimally invasive procedure.

New and breakthrough discoveries.

Braincure Biotech’s Research and Development strategy is to utilize its ImmunoTX (immunotherapeutics) and Smolecs (small molecules) technology platforms to generate a broad array of innovative products for diseases, such as Alzheimer’s that involve misfolded proteins.

Most people living with Alzheimer's are not aware of their diagnosis.

Alzheimer’s disease is a devastating neurodegenerative disease of the central nervous system for which there is no disease-modifying treatment.

Look ahead with hope, we're there.

Braincure Biotech has one of the largest pipeline in the world for the treatment of Alzheimer’s disease and has a comprehensive approach to product development.

About Braincure Biotech

Braincure Biotech is dedicated to pursuing the development and commercialization of novel treatment approaches in the fight against dementias, with a particular focus on Alzheimer’s Disease. Our vision is to apply what we know about the effect of momentum stimulation on improved cognitive function to create a new and more effective treatment paradigm. For the millions of people living with, or in fear of, an Alzheimer’s diagnosis, our success could mean hope for the future and a lifetime preserved. Our goal is the development and commercialization of a medical device with the potential to arrest or significantly slow Alzheimer’s Disease progression.

Our Approach

Braincure has a patent-pending device that is implanted in the omentum, a protective layer of skin that protects the abdominal organs. The device is designed to stimulate the omentum in patients with Alzheimer’s Disease. Omental stimulation has been shown to improve cognitive function in patients with dementias, including Alzheimer’s Disease. Braincure will evaluate the effect of omental stimulation at different intervals and levels of stimulation to determine the device’s ability to slow, stop or reverse the progression of Alzheimer’s Disease on patients.

The Disease

Alzheimer’s disease is a devastating neurodegenerative disease of the central nervous system for which there is no disease-modifying treatment. Alzheimer’s disease is responsible for 60-80% of all cases of dementia and progressively destroys the cognitive abilities of its victims. The disease is named after Dr. Alois Alzheimer who, in 1906, first described brain shrinkage and plaques and tangles in the brain of a woman who died with an unexplained mental illness that featured memory
loss and behavioral instability.

Today, the scientific community suggests that two proteins are implicated in the pathology of Alzheimer’s disease: Amyloid beta (Abeta) and Tau protein. Abeta is a fragment of a larger, membrane-bound protein whose normal function is believed to be in the forming and dissolving of connections between brain cells that are needed for nerve cell communication. According to the Amyloid Cascade Hypothesis, these monomeric fragments of Abeta misfold in a chain reaction, then aggregate to form multi-unit oligomers which then form fibrils that are deposited in the brain as the
amyloid plaques that were first described by Alois Alzheimer.

Caring deeply about those around us

We understand that what we do matters ­— to our patients, our employees and the communities in which we live and work.